AAP
CLDX icon

Arax Advisory Partners’s Celldex Therapeutics CLDX Stock Holding History

Arax Advisory Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5K Buy
550
+461
+518% +$14.9K ﹤0.01% 3944
2026
Q1 		$2.82K Buy
89
+2
+2% +$55 ﹤0.01% 3002
2025
Q4 		$2.36K Buy
+87
New +$2.29K ﹤0.01% 3200
2024
Q4 		– Sell
-139
Closed -$4.72K – 2490
2024
Q3 		$4.72K Hold
139
– – ﹤0.01% 1737
2024
Q2 		$5.14K Buy
+139
New +$5.25K ﹤0.01% 1581

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's CLDX Position: Q2 2026 in Review

Arax Advisory Partners increased its Celldex Therapeutics (CLDX) stake by 518% in Q2 2026, buying an estimated $14.9K and bringing the position to 550 shares worth $20.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3944.

Arax Advisory Partners first reported a position in CLDX in Q2 2024 and has held it in 5 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Arax Advisory Partners held 550 shares of Celldex Therapeutics worth $20.5K as of Q2 2026.
  • Arax Advisory Partners bought 461 Celldex Therapeutics shares in Q2 2026, an estimated $14.9K.
  • Celldex Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3944 holding.
  • Arax Advisory Partners first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.